Search Results - "Goujon, Gael"
-
1
Complete pathological response after chemotherapy or immune checkpoint inhibitors in deficient MMR metastatic colorectal cancer: Results of a retrospective multicenter study
Published in International journal of cancer (01-10-2023)“…About 5% of the patients with metastatic colorectal cancers (mCRC) present microsatellite instability (MSI)/deficient mismatch repair system (dMMR). While…”
Get full text
Journal Article -
2
Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high‐risk Stage II and III colon cancers? Three years' follow‐up results of the PRODIGE 22 phase II randomized multicentre trial
Published in Colorectal disease (01-06-2021)“…Aim Neoadjuvant chemotherapy has proven valuable in locally advanced resectable colon cancer (CC) but its effect on oncological outcomes is uncertain. The aim…”
Get full text
Journal Article -
3
Withholding the Introduction of Anti‐Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild‐Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study)
Published in The oncologist (Dayton, Ohio) (01-02-2020)“…Background Patients with RAS wild‐type (WT) nonresectable metastatic colorectal cancer (mCRC) may receive either bevacizumab or an anti‐epidermal growth factor…”
Get full text
Journal Article -
4
Daily practices in chemotherapy for advanced gastric or gastroesophageal junction adenocarcinoma: METESTOMAC French prospective cohort
Published in Cancer medicine (Malden, MA) (01-03-2023)“…Background Around 50% of gastric cancers are diagnosed at an advanced stage. Several chemotherapy regimens are now internationally validated. Few data are…”
Get full text
Journal Article -
5
Low phospholipid-associated cholelithiasis syndrome: A rare cause of acute pancreatitis that should not be neglected
Published in World journal of hepatology (27-06-2020)“…BACKGROUNDLow phospholipid-associated cholelithiasis (LPAC) syndrome is a very particular form of biliary lithiasis with no excess of cholesterol secretion…”
Get full text
Journal Article -
6
Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study
Published in International journal of cancer (01-07-2020)“…Mismatch repair‐deficient (dMMR) and/or microsatellite instability‐high (MSI) colorectal cancers (CRC) represent about 5% of metastatic CRC (mCRC). Prognosis…”
Get full text
Journal Article -
7
Impact of tobacco smoking on the patient's outcome after (chemo)radiotherapy for anal cancer
Published in European journal of cancer (1990) (01-12-2020)“…Anal squamous cell carcinoma is associated with multiple risk factors, including infection with human papillomavirus and human immunodeficiency virus,…”
Get full text
Journal Article -
8
FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX‐bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study
Published in International journal of cancer (01-12-2022)“…After failure of first line FOLFOX‐bevacizumab for metastatic colorectal cancer (mCRC), adding either bevacizumab or aflibercept to second‐line FOLFIRI…”
Get full text
Journal Article -
9
Prognosis and chemosensitivity of non-colorectal alimentary tract cancers with microsatellite instability
Published in Digestive and liver disease (01-01-2023)“…Data on outcomes of microsatellite instable and/or mismatch repair deficient (dMMR/MSI) digestive non-colorectal tumors are limited. To evaluate overall…”
Get full text
Journal Article -
10
Does neoadjuvant FOLFOX chemotherapy improve the oncological prognosis of high-risk stage II and III colon cancers ? Three years’ follow-up results of the Prodige 22 phase II randomized multicenter trial
Published in Journal of clinical oncology (20-05-2020)“…Abstract only 4110 Background: Neoadjuvant chemotherapy in a perioperative setting has proven valuable in locally advanced resectable colon cancer (CC) in…”
Get full text
Journal Article -
11
Prevalence and prognosis of microsatellite instability in oesogastric adenocarcinoma, NORDICAP 16-01
Published in Clinics and research in hepatology and gastroenterology (01-07-2021)“…•Microsatellite instability prevalence is 12.4%.•Patients in MSI group have a lower cumulative incidence of recurrence after surgery.•There is a 100%…”
Get full text
Journal Article -
12
Efficacy of modern chemotherapy and prognostic factors in patients with ovarian metastases from gastric cancer: A retrospective AGEO multicentre study
Published in Digestive and liver disease (01-04-2016)“…Abstract Background Ovarian metastases from gastrointestinal tumours frequently lead to locoregional complications and undermine quality of life. The…”
Get full text
Journal Article -
13
Colorectal cancer (CRC) patients surveyed by 18 FDGPET-CT (PET-CT): An open-label multicenter randomized trial (NCT 00624260)
Published in Journal of clinical oncology (20-05-2017)“…Abstract only 3520 Background: Curative surgery is the best therapy of CRC and recurrences. We assessed whether adding semi-annual PET-CT to the usual…”
Get full text
Journal Article -
14
A large multicenter study evaluating prognosis and chemosensitivity of metastatic colorectal cancers with microsatellite instability
Published in Journal of clinical oncology (20-05-2017)“…Abstract only 3536 Background: Deficient Mismatch Repair (dMMR) in colorectal cancers (CRC) represent 12% of all tumors. In non-metastatic CRC setting, dMMR…”
Get full text
Journal Article -
15
Complete pathological response after chemotherapy or immune checkpoint inhibitors in deficient MMR metastatic colorectal cancer: Results of a retrospective multicenter study
Published in International journal of cancer (2023)“…About 5% of the patients with metastatic colorectal cancers (mCRC) present microsatellite instability (MSI)/deficient mismatch repair system (dMMR). While…”
Get full text
Journal Article -
16
Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study)
Published in The oncologist (Dayton, Ohio) (02-10-2019)“…Patients with wild-type (WT) nonresectable metastatic colorectal cancer (mCRC) may receive either bevacizumab or an anti-epidermal growth factor receptor…”
Get full text
Journal Article -
17